🇺🇸 FDA

Company profile · Sponsor

Sumitomo

Sumitomo Pharma (Suzhou) Co.,

C40318F · NMPA pharma CN
Pipeline
4
Drugs
0
Patents
0

Quick answer

Sumitomo (C40318F) is a pharma company. headquartered in CN. listed on NMPA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker C40318F
Exchange NMPA
Company type pharma
Headquarters CN

Pipeline (4)

Search pipeline →

  1. Lurasidone

    Sumitomo

    Bipolar I Depression

    phase 3 small molecule completed

    1 trial

  2. Napabucasin

    Sumitomo

    Carcinoma, Pancreatic Ductal

    phase 3 small molecule completed

    1 trial

  3. Placebo

    Sumitomo

    Bipolar Depression

    phase 3 small molecule completed

    1 trial

  4. BBI608

    Sumitomo

    Malignant Pleural Mesothelioma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is Sumitomo?

Sumitomo (C40318F) is a pharma company. headquartered in CN. listed on NMPA. NovaPharmaNews links 4 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Sumitomo sponsor?

We track 4 ClinicalTrials.gov-linked programs for Sumitomo, including Lurasidone and 3 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Sumitomo company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.